# Jennifer A Rothman

List of Publications by Year
in descending order



| 53 | 1,110 | 516561 16 | 414303 32 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 54 | 54 | 54 | 1390 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | SARSâ€CoVâ€2 vaccination in pediatric patients with immune thrombocytopenia. Pediatric Blood and Cancer, 2022, 69, e29760. | 0.8 | 3 |
| 2 | The pyruvate kinase (PK) to hexokinase enzyme activity ratio andÂerythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. British Journal of Haematology, 2021, 192, 1092-1096. | 1.2 | 15 |
| 3 | Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood Cells, Molecules, and Diseases, 2021, 87, 102534. | 0.6 | 3 |
| 4 | Pyruvate kinase deficiency in children. Pediatric Blood and Cancer, 2021, 68, e29148. | 0.8 | 10 |
| 5 | Diagnostic workâ€up for severe aplastic anemia in children: Consensus of the <scp>North American Pediatric Aplastic Anemia Consortium</scp>. American Journal of Hematology, 2021, 96, 1491-1504. | 2.0 | 14 |
| 6 | Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. Blood, 2021, 138, 848-848. | 0.6 | 1 |
| 7 | Osteomyelitis in sickle cell disease: You know it when you see it?. Pediatric Blood and Cancer, 2020, 67, e28585. | 0.8 | 2 |
| 8 | Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281. | 2.0 | 8 |
| 9 | How I approach hereditary hemolytic anemia and splenectomy. Pediatric Blood and Cancer, 2020, 67, e28337. | 0.8 | 8 |
| 10 | Longâ€term hematologic and clinical outcomes of splenectomy in children with hereditary spherocytosis and sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28290. | 0.8 | 5 |
| 11 | Computerized cognitive training in pediatric sickle cell disease: A randomized controlled pilot study.. Clinical Practice in Pediatric Psychology, 2020, 8, 390-401. | 0.2 | 2 |
| 12 | Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. Blood, 2020, 136, 18-19. | 0.6 | 9 |
| 13 | The Spectrum of SPTA1-Associated Hereditary Spherocytosis. Frontiers in Physiology, 2019, 10, 815. | 1.3 | 32 |
| 14 | Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica, 2019, 104, 1974-1983. | 1.7 | 43 |
| 15 | Secondâ€line treatments in children with immune thrombocytopenia: Effect on platelet count and patientâ€centered outcomes. American Journal of Hematology, 2019, 94, 741-750. | 2.0 | 37 |
| 16 | Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53. | 1.7 | 46 |
| 17 | Aberrant splicing contributes to severe Î±-spectrinâ€“linked congenital hemolytic anemia. Journal of Clinical Investigation, 2019, 129, 2878-2887. | 3.9 | 24 |
| 18 | Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency. Blood, 2019, 134, 949-949. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 2175-2175. | 0.6 | 0 |
| 20 | A Retrospective Review of Hospital-Acquired Venous Thromboembolism at a Large Pediatric Tertiary Care Center. Blood, 2019, 134, 3471-3471. | 0.6 | 0 |
| 21 | Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency. Blood, 2019, 134, 3515-3515. | 0.6 | 1 |
| 22 | Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. American Journal of Hematology, 2018, 93, 882-888. | 2.0 | 30 |
| 23 | Bleeding and thrombotic complications of pediatric liver transplant. Pediatric Blood and Cancer, 2018, 65, e26955. | 0.8 | 21 |
| 24 | Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 2018, 131, 2183-2192. | 0.6 | 121 |
| 25 | Further evidence for the involvement of EFL1 in a Shwachmanâ€“Diamond-like syndrome and expansion of the phenotypic features. Journal of Physical Education and Sports Management, 2018, 4, a003046. | 0.5 | 29 |
| 26 | Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. Blood, 2018, 132, 4807-4807. | 0.6 | 1 |
| 27 | The clinical severity of hemoglobin S/Black (<sup>A</sup>Î³Î²)<sup>0</sup>â€thalassemia. Pediatric Blood and Cancer, 2017, 64, e26596. | 0.8 | 5 |
| 28 | Executive functioning and health-related quality of life in pediatric sickle cell disease. Child Neuropsychology, 2017, 23, 889-906. | 0.8 | 25 |
| 29 | Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP). Blood, 2017, 130, 752-752. | 0.6 | 2 |
| 30 | Effects of hydroxyurea treatment for patients with hemoglobin <scp>SC</scp> disease. American Journal of Hematology, 2016, 91, 238-242. | 2.0 | 54 |
| 31 | Trends in Sickle Cell Disease-related Priapism in U.S. Children's Hospitals. Urology, 2016, 89, 118-122. | 0.5 | 10 |
| 32 | Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia. Journal of Clinical Pharmacology, 2016, 56, 298-306. | 1.0 | 14 |
| 33 | Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemiaâ€”TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet, The, 2016, 387, 661-670. | 6.3 | 375 |
| 34 | Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. Journal of Pediatric Surgery, 2016, 51, 122-127. | 0.8 | 39 |
| 35 | Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial. Blood, 2016, 128, 1019-1019. | 0.6 | 4 |
| 36 | Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 249-249. | 0.6 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. Blood, 2016, 128, 1008-1008. | 0.6 | 0 |
| 38 | Comparison of Bleeding Tools in a Cohort of Pediatric Patients with ITP: Data from the Pediatric ITP Consortium of North America ICON1 Study. Blood, 2016, 128, 4752-4752. | 0.6 | 0 |
| 39 | Postoperative Venous Thromboembolism in Children Is Increased in Setting of Cancer or Infection. Blood, 2016, 128, 2391-2391. | 0.6 | 1 |
| 40 | Iron Overload Is Highly Prevalent in All Disease Severity States in Pyruvate Kinase Deficiency (PKD). Blood, 2016, 128, 2430-2430. | 0.6 | 1 |
| 41 | Clinical outcomes of splenectomy in children: Report of the splenectomy in congenital hemolytic anemia registry. American Journal of Hematology, 2015, 90, 187-192. | 2.0 | 33 |
| 42 | TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. Blood, 2015, 126, 3-3. | 0.6 | 19 |
| 43 | Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants. Blood, 2015, 126, 3337-3337. | 0.6 | 4 |
| 44 | The Spectrum of Alpha-Spectrin Associated Hereditary Spherocytosis. Blood, 2015, 126, 941-941. | 0.6 | 2 |
| 45 | The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status. Blood, 2015, 126, 2136-2136. | 0.6 | 1 |
| 46 | Systemic Loxoscelism in a Nonendemic Area. Clinical Pediatrics, 2014, 53, 1098-1100. | 0.4 | 3 |
| 47 | Care of the Oncology Patient in the PICU. , 2014, , 343-361. | | 0 |
| 48 | The Use of Chronic Transfusions in Sickle Cell Disease for Non-Stroke Related Indications. Blood, 2014, 124, 4934-4934. | 0.6 | 1 |
| 49 | Evaluation of partial and total splenectomy in children with sickle cell disease using an internetâ€based registry. Pediatric Blood and Cancer, 2012, 59, 100-104. | 0.8 | 28 |
| 50 | Timing of the Initiation of Hydroxyurea and Hematologic Outcomes in Patients with Sickle Cell Disease (SCD). Blood, 2012, 120, 1004-1004. | 0.6 | 0 |
| 51 | Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMVâ€infected perforinâ€deficient mice. Pediatric Blood and Cancer, 2011, 57, 1239-1243. | 0.8 | 3 |
| 52 | Hydroxyurea Reduces Conversion From Conditional to Abnormal TCD Velocities In Children with Sickle Cell Anemia (SCA). Blood, 2010, 116, 270-270. | 0.6 | 8 |
| 53 | Complications of Implantable Venous Access Devices In Patients with Sickle Cell Disease. Blood, 2010, 116, 1649-1649. | 0.6 | 0 |